


04-19-06

IFW/4

Patent Docket P1718R1C1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Vishva Dixit et al. Serial No.: 10/607,882 Filed: June 27, 2003	Group Art Unit: 1653 Examiner: G. Bugaisky Confirmation No: 7220 CUSTOMER NO: 09157
For: METHODS FOR MAKING RECOMBINANT PROTEINS USING APOPTOSIS INHIBITORS	<div style="text-align: center;"> CERTIFICATE OF EXPRESS MAILING Express Mail Label No.: <u>EV 712 538 635 US</u> </div> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450".</p> <p style="text-align: right;">April <u>18</u>, 2006</p> <p style="text-align: right;"><i>Diane L. Marschang</i> Diane L. Marschang</p>

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☐ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

04/20/2006 BABRAHA1 00000093 070630 10607882

01 FC:1806 180.00 DA

☒ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

☒ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

☒ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.

☒ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449.

A copy of the European Search Report is attached.

Copies of the items listed on the PTO-1449 form are supplied herewith, except for United States patent(s) and United States patent application publication(s) and other documents that are marked with an asterisk (*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR §1.98(a)(2)(ii)]. See Final Rule **1287 OG** (October 12, 2004). Other documents cited with an

asterisk have not been supplied because they were previously cited by or submitted to the Office in prior application Serial No. 09/668,924, filed September 25, 2000 and benefit from the prior application is claimed in this application under 35 U.S.C § 120. However, copies of any cited document will be provided in its entirety at the request of the Office.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: April 18, 2006

By: Diane L. Marschang
Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416



Patent Docket P1718R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Vishva Dixit et al. Serial No.: 10/607,882 Filed: June 27, 2003 For: METHODS FOR MAKING RECOMBINANT PROTEINS USING APOPTOSIS INHIBITORS	Group Art Unit: 1653 Examiner: G. Bugaisky Confirmation No: 7220 CUSTOMER NO: 09157 CERTIFICATE OF EXPRESS MAILING Express Mail Label No.: <u>EV 712 538 635 US</u> I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450". April <u>18</u> , 2006 <i>Diane L Marschang</i> Diane L. Marschang
--	--

TRANSMITTAL LETTER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

1. Supplemental Information Disclosure Statement (dup);
2. Form PTO-1449 with 1 Reference;
3. Return postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.


Respectfully submitted,

GENENTECH, INC.

Date: April 18, 2006

By:

Diane L Marschang
Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1718R1C1Serial No.
10/607,882

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Vishva Dixit et alFiling Date
27 Jun 2003Group
1653

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

67

Sigma - Aldrich, "Mammalian Expression Vectors: Transient Expression" Internet Article,
www.sigmaaldrich.com/Area of Interest/Life Science/Molecular Biology/Cloning and Expression/
Product Lines/Vector Systems/Transient Expression.html (Retrieved on 2/14/2006)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.